Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2025 Apr 30;32(2):101-109.
doi: 10.32604/cju.2025.063073.

Differences at diagnosis between long-term survivors and not long-term survivors in metastatic renal cell carcinoma initially treated with TKI

Miguel Ángel Gómez-Luque  1 , Guillermo Lendínez-Cano  1 , Carmen Belén Congregado-Ruiz  1 , Ignacio Osman-García  1 , Rafael Antonio Medina-López  1
Affiliations
Free article
Comparative Study

Differences at diagnosis between long-term survivors and not long-term survivors in metastatic renal cell carcinoma initially treated with TKI

Miguel Ángel Gómez-Luque et al. Can J Urol. .
Free article

Abstract

Introduction: In recent years, significant advancements in the treatment of metastatic renal cell carcinoma (mRCC) have notably extended overall survival (OS) times, particularly with the introduction of tyrosine kinase inhibitors (TKIs) and combination immunotherapy. However, survival outcomes in mRCC remain highly variable.

Materials and methods: This study retrospectively analyzed clinical and demographic factors at diagnosis in patients treated for mRCC to identify predictors of long-term survival (defined as OS ≥ 48 months). Patients were categorized into long-term survivors (LTS) and non-long-term survivors (nLTS).

Results: The analysis revealed that factors such as better Karnofsky Performance Status (KPS), normal baseline laboratory values (e.g., hemoglobin, calcium), and the presence of lung-only metastases were significantly associated with longer survival. Conversely, comorbid conditions like hypertension and dyslipidemia, poorer KPS, and certain adverse laboratory findings were more common in the nLTS group.

Conclusion: These findings underscore the importance of baseline prognostic factors in predicting survival outcomes and emphasize the need for personalized treatment strategies in mRCC.

Keywords: long-term survival; metastatic renal cell carcinoma; tyrosine kinase inhibitors.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest to report regarding the present study.

Similar articles

See all similar articles

References

    1. Motzer RJ, Tannir NM, McDermott DF et al. 661P conditional survival and 5-year follow-up in CheckMate 214: first-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). Ann Oncol 2021;32:S685–S687. - DOI
    1. Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27(22):3584–3590. - PubMed - DOI
    1. Lemelin A, Takemura K, Heng DYC, Ernst MS. Prognostic models in metastatic renal cell carcinoma. Hematol Oncol Clin North Am 2023;37(5):925–935. - PubMed - DOI
    1. Escudier B, Motzer RJ, Tannir NM et al. Efficacy of nivolumab plus ipilimumab according to number of IMDC risk factors in CheckMate 214. Eur Urol 2020;77(4):449–453. - PubMed - DOI
    1. Rini BI, Plimack ER, Stus V et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. New Engl J Med 2019;380(12):1116–1127. - PubMed - DOI

Publication types

MeSH terms

Substances

LinkOut - more resources